sitagliptin , 97% , 486460-32-6

CAS NO.：486460-32-6

Empirical Formula: C16H15F6N5O

Molecular Weight: 407.31

MDL number: MFCD09838015

EINECS: 690-730-1

PRODUCT Properties

• Melting point: 114.1-115.7 °C
• Boiling point: 529.9±60.0 °C(Predicted)
• Density: 1.61±0.1 g/cm3(Predicted)
• storage temp.: Store at -20°C
• solubility: DMSO : ≥ 50 mg/mL (122.76 mM)
• form: Solid
• pka: 7.20±0.10(Predicted)
• color: White to off-white
• InChI: InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
• InChIKey: MFFMDFFZMYYVKS-SECBINFHSA-N
• SMILES: C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F

Description and Uses

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.

Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-?diabetes, impaired glucose tolerance, hepatitis, and?/or inflammatory liver disease.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338